DB15892ExperimentalVaccines
The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India . The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying... Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a strong immune response, stimulating the humoral and cellular components of the immune system.
- Code names
- Zycov-D
What you can answer from here — as of March 06, 2025
Which companies are running trials of ZYCOV-D, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account